Clinical Trial Update: A Study Of SIBP-01 Or CN-Trastuzumab Plus Docetaxel And Carboplatin In HER2 Positive Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial of CN-Trastuzumab (SIBP-01) with docetaxel and carboplatin in HER2-positive early breast cancer completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• CN-Trastuzumab (CN-Trastuzumab)
• DOCETAXEL (DOCETAXEL)
• SIBP-01 (SIBP-01)

Snippet

Sponsor: Shanghai Institute Of Biological Products | Conditions: HER2-positive Early Breast Cancer | Phase 3 | Status: COMPLETED